IDENTIFICATION OF INTERACTIONS BETWEEN NITRIC OXIDE SYNTHASE AND CALMODULIN

一氧化氮合酶和钙调蛋白之间相互作用的鉴定

基本信息

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Nitric oxide synthase (NOS) plays a role in a variety of physiological functions from smooth muscle relaxation to cell-cell signaling in neurons. This enzyme catalyzes the oxidation of arginine to generate the multifunctional small molecule nitric oxide ("NO). The unregulated production of "NO can lead to a number of pathological conditions such as stroke and Alzheimers disease. There are three distinct isoforms of NOS that are differentially regulated by calmodulin (CaM). The isoforms found in neuronal and endothelial cells are regulated by the reversible binding of Ca2+/CaM, while the form found in macrophages (inducible) binds CaM tight enough to be seemingly irreversible.1 Previous research has demonstrated that the neuronal and the inducible NOS have very different requirements for which Ca2+ binding site of CaM must be Ca2+ bound in order to achieve activation, and suggests that the interactions between CaM and these two NOS isoforms is in opposite orientation.2,3 In lieu of molecular structures of these proteins, understanding this phenomenon requires studies geared at the gradual unraveling of the interactions and then piecing the information back together. The long-term objective of Dr. Stevens-Truss laboratory is to understand the mechanisms underlying CaMs binding to and regulation of NOS. Mass spectrometry offers a tool that can be used to unravel these interactions. Traditional protein fingerprinting methodologies coupled with mass spectrometry are planned for use in this project, in an attempt to develop ways to study the interactions between CaM and the various NOS isoforms. This research is important because (i) it will increase our understanding of the overall folded structure of NOS as it relates to CaM binding and activation, (ii) it will shed light on the still enigmatic role of CaM in binding and activating over 30 different proteins, and (iii) it will advance efforts to design NOS isoform selective inhibitors. Moreover, these studies will aid in our understanding of factors that disrupt protein-protein interactions such as light energy collisions. Nitric oxide synthase (NOS) plays a role in a variety of physiological functions from smooth muscle relaxation to cell-cell signaling in neurons. This enzyme catalyzes the oxidation of arginine to generate the multifunctional small molecule nitric oxide ("NO). The unregulated production of "NO can lead to a number of pathological conditions such as stroke and Alzheimers disease. There are three distinct isoforms of NOS that are differentially regulated by calmodulin (CaM). The isoforms found in neuronal and endothelial cells are regulated by the reversible binding of Ca2+/CaM, while the form found in macrophages (inducible) binds CaM tight enough to be seemingly irreversible.1 Previous research has demonstrated that the neuronal and the inducible NOS have very different requirements for which Ca2+ binding site of CaM must be Ca2+ bound in order to achieve activation, and suggests that the interactions between CaM and these two NOS isoforms is in opposite orientation.2,3 In lieu of molecular structures of these proteins, understanding this phenomenon requires studies geared at the gradual unraveling of the interactions and then piecing the information back together. The long-term objective of Dr. Stevens-Truss laboratory is to understand the mechanisms underlying CaMs binding to and regulation of NOS. Mass spectrometry offers a tool that can be used to unravel these interactions. Traditional protein fingerprinting methodologies coupled with mass spectrometry are planned for use in this project, in an attempt to develop ways to study the interactions between CaM and the various NOS isoforms. This research is important because (i) it will increase our understanding of the overall folded structure of NOS as it relates to CaM binding and activation, (ii) it will shed light on the still enigmatic role of CaM in binding and activating over 30 different proteins, and (iii) it will advance efforts to design NOS isoform selective inhibitors. Moreover, these studies will aid in our understanding of factors that disrupt protein-protein interactions such as light energy collisions.
这个子项目是众多研究子项目之一

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

REGINA STEVENS-TRUSS其他文献

REGINA STEVENS-TRUSS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('REGINA STEVENS-TRUSS', 18)}}的其他基金

IDENTIFICATION OF INTERACTIONS BETWEEN NITRIC OXIDE SYNTHASE AND CALMODULIN
一氧化氮合酶和钙调蛋白之间相互作用的鉴定
  • 批准号:
    7359143
  • 财政年份:
    2006
  • 资助金额:
    $ 3.49万
  • 项目类别:

相似国自然基金

新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
  • 批准号:
    81000622
  • 批准年份:
    2010
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
  • 批准号:
    31060293
  • 批准年份:
    2010
  • 资助金额:
    26.0 万元
  • 项目类别:
    地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
  • 批准号:
    30960334
  • 批准年份:
    2009
  • 资助金额:
    22.0 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
  • 批准号:
    10657993
  • 财政年份:
    2023
  • 资助金额:
    $ 3.49万
  • 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
  • 批准号:
    10381163
  • 财政年份:
    2022
  • 资助金额:
    $ 3.49万
  • 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
  • 批准号:
    10531959
  • 财政年份:
    2022
  • 资助金额:
    $ 3.49万
  • 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
  • 批准号:
    10700991
  • 财政年份:
    2022
  • 资助金额:
    $ 3.49万
  • 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
  • 批准号:
    10518582
  • 财政年份:
    2022
  • 资助金额:
    $ 3.49万
  • 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
  • 批准号:
    10672973
  • 财政年份:
    2022
  • 资助金额:
    $ 3.49万
  • 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
  • 批准号:
    10585925
  • 财政年份:
    2022
  • 资助金额:
    $ 3.49万
  • 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
  • 批准号:
    10180000
  • 财政年份:
    2021
  • 资助金额:
    $ 3.49万
  • 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
  • 批准号:
    10049426
  • 财政年份:
    2021
  • 资助金额:
    $ 3.49万
  • 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
  • 批准号:
    10295809
  • 财政年份:
    2021
  • 资助金额:
    $ 3.49万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了